Therefore, molecules such as GSK-3β, p-GSK-3β, and p53, which can be detected in peripheral blood lymphocytes of AD patients, may be potential therapeutic targets in AD (Arafa and Elghazawy, 2017; Kumari et al., 2022). This evidence concerns the gene GSK3B and Alzheimer disease.